DARZALEX ™ (daratumumab) Approved by Health Canada as the First Human Anti-CD38 Monoclonal Antibody for the Treatment of Multiple Myeloma

Janssen Inc. announces Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving DARZALEX ™ (daratumumab) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are refractory to both a PI and an IMiD. Health Canada approved this product on the conditi on that Janssen Inc. carries out confirmatory trials to verify the clinical benefit of DARZALEX™.

Source: International Myeloma Foundation - July 6, 2016 Category: Hematology Source Type: news